IFN-Y
PreclinicalSmall molecule
IFN-Y is one of 10 small molecule programs targeting Paralysis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Paralysis
#DrugCompanyPhaseTrials
1Robinul
Jazz PharmaceuticalsApproved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Movantik
AAveritas Pharma, Inc.
Approved
Relistor
SSalix
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
GM-CSF
YY-mAbs Therapeutics
Phase 3
Buspar
Bristol-Myers SquibbPhase 1
Bayer Aspirin
BayerPreclinical
Marcaine
IInnocoll
Preclinical
IFN-Y
RRadboud University Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IFN-Y. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details